Coarctation of the aorta (CoA) accounts for 4-8% of congenital heart defects (CHDs) and carries
substantial morbidity despite treatment 1 CoA is defined by local narrowing of the proximal descending aorta and/or aortic arch, causes left ventricular outflow tract obstruction (LVOTO), and typically presents as either heart failure in infants or hypertension later in life 3 . Surgical or interventional treatment considerably improves outcome but risk of premature cardiovascular morbidity and mortality remains despite appropriate therapy 4 .
CoA presents most commonly in a sporadic fashion and is accompanied by BAV in about half of cases, but less commonly with other CHDs 5 . Less frequently, it cosegregates in families with other LVOTO malformations including BAV, congenital aortic valve stenosis and hypoplastic left heart syndrome (HLHS) 6 . The LVOTO malformations as a group are markedly heritable (0.71-0.90) and have a high relative risk for first-degree relatives (36.9) 7 . In addition, around 15% of CoA cases occur as part of a recognized genetic syndrome (e.g. 45,X or Turner) 8 .
Not much is known about genetic causes of non-syndromic CoA. Several studies have found mutations in families with LVOTO malformations and a few cases of sporadic CoA, both with and without concomitant CHDs. The most strongly implicated gene is NOTCH1 9-11 , encoding a transmembrane receptor that regulates cell fate during development. Mutations in other genes, including MYH6 12, 13 , SMAD6 14 , NKX2-5 15 and GATA5 16 , have been found in one or few cases of CoA. The MYH6 mutations were found in two families of CoA cases, one with predisposition to atrial septal defect (ASD) 12 and the other to HLHS 13 . In addition, knockout animal models of several genes found within copy number variants in CoA cases in man, including MCTP2 17 , MATR3 18 and FOXC1 19 , have been shown to result in CoA-like phenotypes.
To search for sequence variants that associate with non-syndromic CoA, we performed a GWAS including 120 Icelandic cases and 355,116 population controls. We tested 32.5 million sequence variants (SNPs and INDELs) identified through whole-genome sequencing (WGS) of 15,220 Icelanders (median coverage 32X) and imputed into 151,677 chip-typed, long-range phased Icelanders and their close relatives. The utilization of long-range phased haplotypes enables accurate imputation of variants with frequency down to approximately 0.02% in this data set. We performed association testing using logistic regression adjusting for gender, age and county. The threshold for genome-wide significance was set using a class-specific Bonferroni procedure based on functional impact of classes of variants 20 .
The 120 CoA cases were diagnosed between the years 1950 and 2016, with most cases (75%) diagnosed after 1990. We show the phenotypic characteristics of the CoA cases in Supplementary   Table 1 . About half were diagnosed during the first month of life and three quarters during the first year of life. As expected 4 , CoA was more common in males than in females (1.6:1). About three quarters of cases had other concomitant CHDs, most commonly BAV and ventricular septal defect (VSD). Similar to other studies 21 , the aortic valve was bicuspid in about half of CoA cases.
We observed a genome-wide significant association with CoA at chromosome 14q11 (Figure 1) , explained by a rare (allele frequency = 0.34%) missense mutation p.Arg721Trp (c.2161C>T) in MYH6, encoding the alpha myosin heavy chain subunit (aMHC) in cardiac muscle. aMHC is a main component of the sarcomere, the basic contractile unit of cardiac muscle 22 . P.Arg721Trp associated with CoA with an OR of 44.2 (95% confidence interval (CI) 20.5 -95.5) and P = 5.01 × 10 -22 (genome-wide significance threshold for missense variants was set at 6.5 × 10 -8 , see Methods) 20 (Figure 2) . None of the genotyped cases or controls (N = 151,677) were homozygous for the mutation, consistent with its low frequency (1.8 homozygotes expected under Hardy-Weinberg equilibrium). Since we observed no homozygotes, we could not discriminate between the dominant and the multiplicative modes of inheritance.
The p.Arg721Trp mutation is located in exon 18 (out of 39 exons) of MYH6 and leads to a missense arginine to tryptophan alteration at amino acid 721 (full-length protein 1939 amino acid) ( Supplementary Figure 1) . It is located in the converter domain of αMHC ( Supplementary Figure 1 and 2), a small domain crucial in conveying a conformational change from the active site to the lever arm upon adenosine triphosphate (ATP) hydrolysis 23 . It is considered likely that the mutation alters To determine whether there were phenotypic differences between carriers (n=24) and non-carriers (n=96) of the p.Arg721Trp mutation within the CoA sample set, we evaluated the frequencies of various clinical characteristics between the two groups (Supplementary Table 2 ). Carriers were nominally more likely to present with mild rather than more critical and complex forms of CoA (OR = 4.2 and P = 0.023). We observed no other differences. The p.Arg721Trp mutation thus appears to be absent from other populations or present at a very low frequency. The Icelandic population is a founder population in that a small number of ancestors account for a relatively large proportion of genetic diversity in the population. Hence, sequence variants that are very rare in more outbred populations may be more frequent in Icelanders, like p.Arg721Trp 25 .
Very rare mutations in MYH6, other than p.Arg721Trp, have been linked to various CHDs 12,13,26 , particularly familial ASD 27, 28 and both dilated and hypertrophic cardiomyopathy (HCM) 29 . In all instances, these mutations have been restricted to a few sporadic cases or to few families. In two of these families, one with predisposition to ASD 12 and the other to HLHS 13 , some of the affected family members had other cardiac defects, including CoA. The MYH6 p.Arg721Trp contrasts these rare familial mutations as it associates with CoA at the population level and explains about 20% of CoA cases in Iceland.
We have previously demonstrated that p.Arg721Trp associates strongly with SSS and AF, atrial arrhythmias that are common in the elderly and frequently coexist 2 ( Table 1 ). In the context of assessing effects of AF risk variants on cardiac conduction, we have also recently found that p.Arg721Trp associates with many ECG measures corresponding to a widespread effect on cardiac electrical function 30 (Supplementary Figure 3) .
To further explore the effect of the p.Arg721Trp MYH6 mutation, we tested it for association with additional cardiac phenotypes, including other CHDs, common heart diseases and several echocardiogram variables ( Table 1, Supplementary Table 3 Figure 3 ; significance threshold set at P < 0.003 (0.05 / 17 individual phenotypes tested). The p.Arg721Trp mutation associated with increased risk of several CHDs: BAV, VSD, ASD and patent ductus arteriosus ( Table 1) .
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As expected, the strongest association was with BAV (OR = 10.5 and P = 7.3 × 10 -8 ). In addition, the mutation associated with late onset aortic valve stenosis. To assess if p.Arg721Trp associates with CHDs in the absence of diagnosed CoA, we re-tested for association after removing CoA cases from the analysis. Although the effect of p.Arg721Trp is consistently weaker, the associations remain (Supplementary Table 3 ). We cannot exclude the existence of undiagnosed CoA in these cases. The mutation also associated with heart failure and ischemic stroke and with diameter of the left atrium but not with other variables derived from the echocardiographic data such as aortic root diameter or left ventricular end-diastolic diameter ( Table 1 ). The p.Arg721Trp mutation did not associate with hypertension or coronary artery disease.
The major components of cardiac muscle myosin are aMHC and beta myosin heavy chain (βMHC) encoded by MYH6 and MYH7, respectively. Both aMHC and βMHC are expressed throughout the heart during embryonic cardiogenesis whereas in the adult heart aMHC is predominantly expressed in the atrium 31 . Expression of MYH6 has not been detected in the aorta (http://gtexportal.org).
The pathogenesis of CoA is not well understood. One of the main models of CoA pathogenesis, the hemodynamic theory 3, 32 , stipulates that cardiac lesions resulting in decreased left ventricular outflow promote development of CoA by reducing blood flow through the fetal aorta. The p.Arg721Trp mutation could predispose to CoA by reducing blood flow through the fetal aorta because of diminished contraction of the developing heart. This hypothesis is supported by overexpression studies in rat cardiomyocytes showing that the p.Arg721Trp mutation impairs sarcomeric structure 33 and by our ECG data demonstrating widespread effect of p.Arg721Trp on cardiac electrical function, including in the ventricles. Our hypothesis is compatible with the fact that MYH6 is expressed in the ventricles during the development of the heart but not in the aorta.
In summary, through GWAS based on WGS, we found a rare missense mutation in the sarcomere gene MYH6 that has a strong effect on the risk of CoA in the Icelandic population and explains a substantial fraction of Icelandic CoA cases. The same mutation also associates with other CHDs, in particular BAV.
It has a widespread effect on cardiac electrical function and associates strongly with atrial arrhythmias, both SSS and AF, suggesting a cardiac syndrome with highly variable expressivity that is difficult to identify clinically without sequence information. This is the first mutation associated with non-familial or sporadic form of CoA at a population level. This discovery gives important insights into the pathophysiology of CoA, supporting the hemodynamic theory of defect development. Measurements were adjusted for sex, year of birth and age at measurement and were subsequently standardized to have a normal distribution. Electrocardiogram (ECG) data was collected from LUH in Reykjavik and included all ECGs obtained and digitally stored from 1998 to 2015, a total of 434,000
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ECGs from up to 88,217 individuals.
Genotyping, imputation and whole-genome sequencing
For chip genotyping, 151,677 samples were typed with the Illumina HumanHap300, HumanCNV370, HumanHap610, HumanHap1M, HumanHap660, Omni-1, Omni 2.5 or Omni Express bead chips at deCODE genetics. Chip SNPs were excluded if they had (1) yield less than 95%, (2) minor allele frequency less than 1% in the population or (3) significant deviation from Hardy-Weinberg equilibrium (P<0.001), (4) if they produced an excessive inheritance error rate (over 0.001) and (5) if there was substantial difference in allele frequency between chip types (from just a single chip if that resolved all differences, but from all chips otherwise). All samples with a call rate below 97% were excluded from the analysis. The final SNP set used for long-range phasing comprised 676,913 autosomal SNPs.
Long range phasing of all chip-genotyped individuals was performed with methods described previously 36, 37 . In brief, phasing is achieved by using an iterative algorithm that phases a single proband at a time given the available phasing information about everyone else that shares a long haplotype identically by state with the proband. Given the large fraction of the Icelandic population that has been chip-typed, accurate long range phasing is available genome-wide for all chip-typed Icelanders.
For long-range phased haplotype association analysis, we then partitioned the genome into nonoverlapping fixed 0.3 cM bins. Within each bin, we observed the haplotype diversity described by the combination of all chip-typed markers in the bin. In the sequencing dataset SNPs and INDELs were identified and genotypes called using joint calling with the Genome Analysis Toolkit HaplotypeCaller (GATK version 3.3.0) 38 . Genotype calls were improved by using information about haplotype sharing, taking advantage of the fact that all the sequenced individuals had also been chip-typed and long-range phased.
The sequence variants identified in the 15,220 sequenced Icelanders were then imputed into 151,677
Icelanders who had been genotyped with various Illumina SNP chips and their genotypes phased using long-range phasing 36, 37 . The imputation into the chip typed long-range phased individuals was performed with the same model as used by IMPUTE 39 . Using genealogic information on Icelanders from The Book of Icelanders 40 , the sequence variants were imputed into first and second-degree relatives of array genotyped individuals to further increase the sample size for association analysis and to increase the power to detect associations. We identified 32.5 million high quality sequence variants (all with imputation information >0.8 that mapped to build hg38) that were tested for association with CoA under the multiplicative model.
Association analysis
Association testing for case-control analysis was performed using logistic regression, adjusting for gender, age and county. A total of 32.5 million variants were used in the association analysis under a multiplicative model.
To account for inflation in test statistics due to cryptic relatedness and stratification, we applied the method of LD score regression 41 . With a set of 1.1M variants, we regressed the χ 2 statistics from our genome-wide association scan against LD score and used the intercept as a correction factor. The LD scores were downloaded from a LD score database 41 . The estimated correction factor was 1.04 for the multiplicative model of the CoA association.
To correct for multiple testing we used the weighted Holm-Bonferroni method 42 When testing the association of p.Arg721Trp with several other cardiac phenotypes, the controls used consisted of disease-free controls randomly drawn from other genetic studies at deCODE.
Phenotypic differences between carriers and non-carriers of p.Arg721Trp
To analyze if CoA carriers of the p.Arg721Trp mutation differed clinically from non-carrier CoA cases, we evaluated the frequencies of various clinical characteristics in these two groups of CoA cases ( Supplementary Table 1 ). Fisher's exact test was used to test for significant difference in the mean frequency of the variants between non-carriers and carriers, and the odds ratio (OR) was calculated as (pa/(1-pa)) / (pc/(1-pc)), where pa and pc are the mean frequencies of the variants in non-carriers and carriers, respectively.
